HOLX (Hologic, Inc.) רווח נקי למניה (EPS TTM)

Hologic, Inc. (HOLX) produces diagnostic equipment, yet faces post-pandemic revenue declines and competition within the gynecology sector. The trailing twelve-month EPS confirms these trends, with the metric currently standing at 2.39. Strict regulatory oversight and the high cost of testing create barriers to entry for new competitors. Meanwhile, high margins on consumables provide the liquidity necessary to reduce debt.

Earnings per share (EPS TTM) measures the actual return on each share of ownership, aggregating financial results over the last four quarters to assess the fundamental efficiency of the business. This chart of trailing 12-month earnings per share demonstrates how Hologic, Inc. (HOLX) leadership in molecular diagnostics and mammography converts a steady stream of consumable payments into sustainable growth in shareholder equity.